[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"uterine-serous-carcinoma-usc\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:uterine-serous-carcinoma-usc":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100552724",false,"NCT06476808","A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.","A Phase 1\u002F1b First-in-human Study of BMS-986463 in Advanced Malignant Tumors","Inclusion Criteria\n\n* Participants must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1.\n* Participants must have at least 1 lesion accessible for biopsy in addition to the target lesion, from which a fresh pre treatment biopsy must be obtained.\n* Participants must have an unresectable\u002Fmetastatic carcinoma.\n\nExclusion Criteria\n\n* Participants must not have Leptomeningeal metastases.\n* Participants must not have concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 2 years prior to treatment.\n* Participants must not have had any prior radiation therapy within 2 weeks prior to start of study treatment.\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.","ALL","18 Years",{"count":18,"type":19},240,"ESTIMATED","INTERVENTIONAL",[22],"PHASE1","The purpose of this study is to evaluate the safety, tolerability, and efficacy of escalating doses of BMS-986463 in participants with select advanced malignant tumors.",[25,26,27],"High-grade Serous Ovarian Carcinoma (HGSOC)","Uterine Serous Carcinoma (USC)","Non-small Cell Lung Cancer (NSCLC)","RECRUITING","2026-04-13",{"date":31,"type":32},"2026-04-15","ACTUAL",{"date":34,"type":32},"2024-09-06",{"date":36,"type":19},"2028-12-19",{"name":38,"class":39},"Bristol-Myers Squibb","INDUSTRY",17,""]